Published online Apr 15, 2018. doi: 10.4251/wjgo.v10.i4.103
Peer-review started: December 22, 2017
First decision: January 6, 2018
Revised: February 1, 2018
Accepted: March 6, 2018
Article in press: March 6, 2018
Published online: April 15, 2018
A pancreatic cancer with liver metastasis.
Amplification of the EGFR gene is targetable in pancreatic acinar carcinoma.
Histology and molecular biology are required for the diagnosis.
Genetic testing provides information on targetable tumor mutation.
Computed tomography scan underlines liver metastasis necrosis.
The patient was treated with off-label usage of panitumumab.
This is the first report of EGFR amplification in acinar cell pancreatic cancer, and the first report of panitumumab efficacy in such disease.
Our findings suggest that exome analysis may be a helpful tool to highlight targets in rare cancers, such as pancreatic acinar cell carcinoma. EGFR amplification in this pathology should be determined and could be used as biomarker to propose antiEGFR therapy.